Brief: China Nt Pharma Group Says Unit Entered Licensing & Collaboration Agreement With Abcentra LLC
21/06/2022 16:21
June 21 (Reuters) - China NT Pharma Group Company Ltd
1011.HK :
* UNIT ENTERED INTO LICENSING & COLLABORATION AGREEMENT WITH
ABCENTRA LLC
* ABCENTRA LLC TO IRREVOCABLY GRANT UNIT EXCLUSIVE AND
PERPETUAL
LICENSE TO COMMERCIALISE MONOCLONAL ANTIBODY TECHNOLOGY
* LICENSE FOR COMMERCIALISATION OF THE TECHNOLOGY GRANTED IN
THE
PRC, HK, MACAU, TAIWAN, SINGAPORE, MALAYSIA & THAILAND
* IS IN ADVANCED STAGE OF DISCUSSION WITH A POTENTIAL
PURCHASER
FOR POTENTIAL DISPOSAL OF CERTAIN ASSETS OF SUZHOU FIRST
Source text for Eikon: ID:nHKS9FS5yS
Further company coverage: 1011.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on China NT Pharma
See all newsBrief: China NT Pharma Receives Cietac Beijing Arbitration Award On July 20
Brief: China NT Pharma Establishes Formal Whistleblowing Policy
Brief: China NT Pharma Group Says Zhang Bozhi Resigns As CEO
Brief: China NT Pharma Group Says Expected Loss For Year Further Reduced By HK$15.4 Million As Compared With Prior Guidance
Brief: China Nt Pharma Expects Net Loss Attributable Of RMB25 MLN To RMB30 MLN In FY